Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sun Pharmaceutical Industries Ltd's Subsidiary Announces USFDA Approval For Generic Doxil


Monday, 4 Feb 2013 10:42pm EST 

Sun Pharmaceutical Industries Ltd announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCl Liposome Injection USP, 2mg/ml_, packaged in 20 mg/lQmL and SO mg/25tnL single-use vials. This generic Doxorubicin HCl Liposome injection USP, 2 mg/mt_ is therapeutically equivalent to Doxil Liposome Injection, 2 mg/mL of Janssen Research and Development, LLC. Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy. 

Company Quote

809.25
-2.75 -0.34%
19 Dec 2014